Theodore G Liou^{1,2,*,§}, Natalia Argel³, Fadi Asfour², Perry S Brown⁴, Barbara A Chatfield^{2,†}, David R Cox^{5,†}, Cori

1

2

3

Associations of Sputum Biomarkers with Clinical Outcomes in People with Cystic Fibrosis

- L Daines⁶, Dixie Durham⁵, Jessica A Francis^{1,7}, Barbara Glover⁸, My Helms¹, Theresa Heynekamp⁹, John R
 Hoidal¹, Judy L Jensen¹, Christiana Kartsonaki¹⁰, Ruth Keogh¹¹, Carol M Kopecky¹², Noah Lechtzin¹³, Yanping
 Li¹, Jerimiah Lysinger¹⁴, Osmara Molina⁶, Craig Nakamura⁸, Kristyn A Packer¹, Robert Paine III¹, Katie R
 Poch¹⁵, Alexandra L Quittner¹⁶, Peggy Radford³, Abby J Redway⁹, Scott D Sagel¹², Rhonda D Szczesniak^{17,18},
 Shawna Sprandel¹⁴, Jennifer L Taylor-Cousar^{15,19}, Jane B Vroom^{1,2}, Ryan Yoshikawa⁸, John P Clancy^{18,8}, J Stuart
 Elborn^{20,8}, Kenneth N Olivier^{21,8}, Frederick R Adler^{22,8}
- 11 Affiliations:
- 12 ¹Adult Cystic Fibrosis Center, Division of Respiratory, Critical Care and Occupational Pulmonary Medicine,
- 13 Department of Internal Medicine, University of Utah, 26 North Mario Capecchi Drive, Salt Lake City, UT
- 14 84132, USA (Dr Liou, ted.liou@utah.edu; Dr. Helms, my.helms@hsc.utah.edu; Dr Hoidal,
- 15 john.hoidal@hsc.utah.edu; and Ms Jensen, judy.jensen@hsc.utah.edu; Ms Packer, kristyn.packer@hsc.utah.edu;
- 16 Dr Paine, robert.paine@hsc.utah.edu; Ms Vroom, jane.vroom@hsc.utah.edu; and Ms Li,
- 17 <u>yanping.li@hsc.utah.edu</u>);
- 18 ²Primary Children's Cystic Fibrosis Center, Division of Pediatric Pulmonology, Department of Pediatrics,
- 19 University of Utah, 81 North Mario Capecchi Drive, Salt Lake City, UT 84113, USA (Drs Liou; Asfour,
- 20 <u>fadi.asfour@hsc.utah.edu</u> and Chatfield[†] and Ms Vroom);
- 21 ³Cystic Fibrosis Center, Phoenix Children's Hospital, 1919 East Thomas Road, Phoenix, AZ 85016, USA (Ms
- 22 Argel, <u>nargel@phoenixchildrens.com</u> and Dr Radford, <u>peggy_radford@hotmail.com</u>);
- ⁴St. Luke's Cystic Fibrosis Center of Idaho, 610 W. Hays Street, Boise, ID 83702, USA (Dr Brown,
- 24 perry.brown@fmridaho.org and Ms Durham, durhamd@slhs.org);
- ⁵Nuffield College, 1 New Rd, Oxford OX1 1NF, UK (Prof Sir David Cox);
- 26 ⁶Division of Pediatric Pulmonary and Sleep Medicine, Department of Pediatrics, University of Arizona Health
- 27 Sciences, 1501 N. Campbell Avenue, Room 3301, PO Box 245073, University of Arizona, Tucson, AZ 85724, NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 28 USA (Dr Daines, <u>cdaines@email.arizona.edu</u> and Ms Molina, <u>omolina@u.arizona.edu</u>);
- 29 ⁷Current Affiliation with ICON Plc (Ms Francis, jessicabakerfrancis@gmail.com);
- 30 ⁸Cystic Fibrosis Center, 3006 S. Maryland Pkwy, Suite #315, Las Vegas, NV 89109, USA (Ms Glover,
- 31 <u>bglover1619@gmail.com;</u> Dr Nakamura, <u>kerristrawberry@yahoo.com;</u> and Mr Yoshikawa,
- 32 <u>rmyoshika@gmail.com</u>);
- ⁹Adult Cystic Fibrosis Program, Division of Pulmonary, Critical Care and Sleep Medicine, DoIM MSC10-5550,
- 34 1 University of New Mexico, Albuquerque, NM 87131, USA (Dr Heynekamp@salud.unm.edu
- 35 and Ms Redway, <u>ajredway@salud.unm.edu</u>);
- ¹⁰Clinical Trial Service Unit & Epidemiological Studies Unit and Medical Research Council Population Health
- 37 Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom (Dr
- 38 Kartsonaki, <u>christiana.kartsonaki@dph.ox.ac.uk</u>);
- 39 ¹¹Department of Medical Statistics, London School of Hygiene and Tropical Medicine, Keppel Street, London,
- 40 UK WC1E 7HT, United Kingdom (Dr Keogh, <u>ruth.keogh@lshtm.ac.uk</u>);
- 41 ¹²Department of Pediatrics, Children's Hospital Colorado and University of Colorado Anschutz Medical
- 42 Campus, 13123 East 16th Avenue, Aurora, CO 80045, USA (Ms Kopecky,
- 43 <u>carol.kopecky@childrenscolorado.org</u> and Dr Sagel, <u>scott.sagel@childrenscolorado.org</u>);
- 44 ¹³Division of Pulmonary and Critical Care and Sleep Medicine, Department of Medicine, Johns Hopkins
- 45 University School of Medicine, 1830 E. Monument Street, Baltimore, MD 21205, USA (Dr Lechtzin,
- 46 <u>nlechtz1@jhmi.edu</u>);
- 47 ¹⁴Montana Cystic Fibrosis Center, Billings Clinic, 2800 10th Avenue N, Billings, MT 59101, USA (Dr Lysinger,
- 48 jlysinger@billingsclinic.org and Ms Sprandel, <u>ssprandel@billingsclinic.org</u>);
- 49 ¹⁵Division of Pulmonary and Critical Care and Sleep Medicine, Department of Medicine, National Jewish
- 50 Health, 1400 Jackson Street, Denver, CO 80206, USA (Ms Poch, pochk@njhealth.org and Dr Taylor-Cousar,
- 51 <u>taylor-cousarj@njhealth.org</u>);
- ¹⁶Behavioral Health Systems Research, Miami, FL, 33133 (Dr. Quittner, aquittner0202@gmail.com);
- ¹⁷Division of Biostatistics & Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH,

- 54 USA (Dr Szczesniak, <u>Rhonda.Szczesniak@cchmc.org</u>);
- ¹⁸Former: Division of Pulmonary Medicine, Department of Pediatrics, University of Cincinnati, Cincinnati, OH,
- 56 USA; Current: Cystic Fibrosis Foundation, 4550 Montgomery Avenue, Bethesda, MD 20814, USA (Dr Clancy,
- 57 john.clancy@cchmc.org);
- ¹⁹Division of Pulmonology, Department of Pediatrics, National Jewish Health, 1400 Jackson St, Denver, CO
- 59 80206, USA (Dr Taylor-Cousar);
- 60 ²⁰Centre for Infection and Immunity, School of Medicine, Dentistry and Biomedical Sciences, Queen's
- 61 University, Health Sciences Building, Lisburn Rd, Belfast BT9 7AE, UK and Respiratory Group in CF, Faculty
- 62 of Medicine, Royal Brompton Hospital, Imperial College, Sydney Street, London SW3 6NP, UK (Dr Elborn,
- 63 <u>s.elborn@qub.ac.uk</u>);
- 64 ²¹Laboratory of Chronic Airway Infection, Pulmonary Branch, National Heart Lung and Blood Institute,
- 65 National Institutes of Health, 10 Center Drive MSC1454, Building 10-CRC, Room 1408A, Bethesda, MD
- 66 20892, USA (Dr Olivier, <u>olivierk@nhlbi.nih.gov</u>);
- 67 ²²Department of Mathematics, 155 South 1400 East, and School of Biological Sciences, 257 South 1400 East,
- 68 University of Utah, Salt Lake City, UT 84112, USA (Dr Adler, adler@math.utah.edu).
- 69
- ^{*}Corresponding Author: Theodore G. Liou, MD, 26 North Mario Capecchi Drive, Salt Lake City, UT 84132,
- 71 USA; email: <u>ted.liou@utah.edu</u>.
- ⁷² [†]In Memoriam: Dr. Barbara A Chatfield, August 25, 1959—October 8, 2016; Professor Sir David Roxbee Cox,
- 73 July 15, 1924—January 18, 2022.
- ⁵Authors are alphabetical except first (TGL), advisory committee (JPC, JSE, KNO) and senior (FRA).
- 75 Abstract: 238 words.
- 76 Manuscript Text: 2,946 words

77 Abstract

78	Background: Airway inflammation promotes bronchiectasis and lung injury in cystic fibrosis (CF).
79	Amplification of inflammation underlies pulmonary exacerbations of disease. We asked whether sputum
80	inflammatory biomarkers provide explanatory information on pulmonary exacerbations.
81	Patients and Methods: We collected sputum from randomly chosen stable adolescents and adults and
82	prospectively observed time to next exacerbation, our primary outcome. We evaluated relationships between
83	potential biomarkers of inflammation, clinical characteristics and outcomes and assessed clinical variables as
84	potential confounders or mediators of explanatory models. We assessed associations between the markers and
85	time to next exacerbation using proportional hazard models adjusting for confounders.
86	Results: We enrolled 114 patients, collected data on clinical variables [December 8, 2014 to January 16, 2016;
87	46% male, mean age 28 years (SD 12), mean percent predicted forced expiratory volume in 1 s (FEV ₁ %) 70
88	(SD 22)] and measured 24 inflammatory markers. Half of the inflammatory markers were plausibly associated
89	with time to next exacerbation. Age and sex were confounders while we found that FEV ₁ % was a mediator.
90	Three potential biomarkers of RAGE axis inflammation were associated with time to next exacerbation while
91	six potential neutrophil-associated biomarkers indicate associations between protease activity or reactive
92	oxygen species with time to next exacerbation.
93	Conclusion: Pulmonary exacerbation biomarkers are part of the RAGE proinflammatory axis or reflect
94	neutrophil activity, specifically implicating protease and oxidative stress injury. Further investigations or
95	development of novel anti-inflammatory agents should consider RAGE axis, protease and oxidant stress
96	antagonists.
97	

98 Tweetable abstract: Sputum from 114 randomly chosen people with CF show RAGE axis inflammation,

99 protease and oxidative stress injury are associated with time to next pulmonary exacerbation and may be targets

100 for bench or factorial design interventional studies. (242 characters)

102 Introduction

103	Airway inflammation erodes lung health in cystic fibrosis (CF). Infecting organisms initiate and amplify
104	inflammation in infants with CF (1). Infections persist, interact (2) and lead to airway obstruction, mucus
105	impaction, antibiotic resistant microbial biofilms and bronchiectasis. Consequences include strenuous treatment
106	burdens, reduced quality of life, hospitalizations for pulmonary exacerbations and early mortality (3).
107	Nine variables summarize clinical CF and durably and successfully predict survival (4, 5) but do not
108	explain inflammatory pathways underlying clinical disease and outcomes. Seeking explanations quantitatively
109	linking inflammation to clinical outcomes, we previously found that high mobility group box 1 (HMGB1)
110	adjusted by number of prior pulmonary exacerbations was associated with time to next exacerbation in a
111	proportional hazards model (6). Other biomarkers may help identify and explain inflammatory pathway roles in
112	CF. In particular, calprotectin (a heterodimer of S100A8 and S100A9), neutrophil elastase (NE) were associated
113	with subsequent pulmonary exacerbations (7–9) in single center studies. None of the study cohorts fully
114	represented people with CF, and no study considered confounding (10) or mediation (11) of inflammatory
115	relationships by clinical covariables.
116	To potentially validate calprotectin, NE or HMGB1, or identify other biomarkers as explanatory for
117	clinical CF outcomes, we performed a prospective observational multicenter study incorporating randomized
118	selection to minimize observer bias and maximize generalizability (12). We collected sputum during clinical
119	stability as the least invasive sample closest to sources of persistent airway inflammation and evaluated clinical
120	covariables for confounding and mediation of biomarker effects leading to a pulmonary exacerbation. This
121	strategy does not seek a prediction model (13), but rather searches for insights into pathways underlying
122	pulmonary exacerbations in CF, seeking specific targets for further investigation and potentially novel

- 123 interventions.
- 124
- 125 Methods
- 126 Study Design and Patients

127 We previously published a detailed study design (12). Briefly, we randomly selected patients with CF 12

128 years and older from accredited care centers for a prospective observational study of sputum biomarkers of 129 airway inflammation. Our primary outcome was time to next pulmonary exacerbation defined as the number of 130 days between enrollment and first hospitalization for acute treatment of at least one symptom and one objective 131 sign of exacerbation of CF (6).

After institutional reviews (Supplemental Table 1), we obtained written informed consent from adults 132 and assent from adolescents with parental consent before enrolling clinically stable participants at outpatient 133 134 visits from December 8, 2014 through January 16, 2016. We collected, processed, aliquoted, froze expectorated 135 sputum samples within 4 hours of collection (mean 54 minutes, SD = 98 minutes, max = 225 minutes on ice) and annotated with clinical information (12). We measured forced expiratory volume in 1 s (FEV₁) according to 136 137 American Thoracic Society Guidelines (14) and estimated percent predicted FEV₁ (FEV₁%) using third 138 National Health and Nutrition Examination Study (NHANES III) equations (15). Prior year exacerbations counts were based on hospitalization dates within one year prior to enrollments. We calcuated weight-for-age z-139 score and 5-year prognostic scores, with higher scores indicating longer predicted survival (4). 140

141

142 Biomarker Measurements

The Pediatric Clinical Translational Research Center Core Laboratory at Colorado Children's Medical 143 144 Center measured NE activity spectrofluorometrically (7). The University of Utah CF Center lab measured Calprotectin, C-reactive protein (CRP), and HMGB1 by enzyme linked immunosorbent assays (ELISA) using 145 commercially available antibodies (Supplemental Table 2). We shipped samples on dry ice (Fedex, Memphis, 146 147 TN. USA) to R&D Systems' Biomarker Testing Service to assay remaining cytokines using their Human Magnetic Luminex Screening Assav Premixed Multi-Analyte Kits (Cat # LXSAHM-16 and LXSAHM-04). We 148 used quantile plots to visually ascertain (16) upper and lower limits of detection. Log-transformed 149 concentrations above or below the limits of detection were assigned values 0.1% above or below the limits of 150 detection, respectively, to retain the partial information. 151

153 Statistical Analysis

We compared clinical measurements that predict CF survival (4, 5) between participants with at least one pulmonary exacerbation in the year following enrollment and those without exacerbations. We obtained Kaplan-Meier (17) estimates of the distribution of time to next pulmonary exacerbation stratified by clinical variables, followed by evaluations using logistic regression (18) and proportional hazards models (19). For logistic regression, we used the occurrence of the next exacerbation during study follow up as the outcome with clinical variables as the inputs, and for proportional hazards models, we used time to next exacerbation as the outcome with the clinical variables as explanatory variables.

161 We evaluated collinearity among biomarker measurements adjusted for detection limits with Pearson 162 Product Moment Correlations (20). We considered p < 0.01 after Bonferroni correction as statistically

163 significant.

Age, sex and prior pulmonary exacerbations may confound time-to-next pulmonary exacerbation but by 164 definition cannot be mediators thus should be included to adjust models (10). To help assess whether other 165 166 clinical variables were confounding, mediating or both (11) for associations of biochemical markers with time to next pulmonary exacerbation, we fitted univariable linear regression models of age, weight-for age z-score, 167 diabetes and FEV₁% as outcomes with each potential biomarker as explanatory variable. We fitted quasi-168 169 Poisson models of prior pulmonary exacerbations with each potential biomarker. We tested each potential biomarker as an adjustment to each of the remaining potentially mediating clinical variables (weight-for-age z-170 score, diabetes and FEV₁%) in proportional hazards models for time to next pulmonary exacerbation. We 171 excluded variables that substantially reduced biomarker effect sizes and significance, indicating a mediation 172 effect. 173

We fitted a regression model for each biomarker with 5-year prognostic risk score variables (4, 5) dependent, using the appropriate regression method as appropriate: linear regressions for age, FEV_1 % and weight-for-age *z*-score; quasi-Poisson regression for pulmonary exacerbation count in the year prior to enrollment; logistic regressions for pancreatic sufficiency, diabetes and status of infections with MSSA and *Burkholderia cepacia* complex. Because of their clinical importance (3, 21), we evaluated relationships between

179 MRSA and *Pseudomonas aeruginosa* status with potential biomarkers using logistic regression. 180 To develop potentially explanatory models for our primary outcome, time to next pulmonary 181 exacerbation, we fitted univariable proportional hazards models (19) for each biomarker, adjusted for confounding variables and excluded mediating variables identified by mediation analysis (11). For each set of 182 models, we accounted for multiple testing using FDR analysis (22) for cutoff values of 0.001, 0.01, 0.05, 0.1 183 184 and 0.2 to understand the support for discovered associations for different biomarkers. 185 186 Sensitivity Analyses We assessed sensitivity of models to anti-inflammatory treatments including inhaled and oral steroids, 187 188

We assessed sensitivity of models to anti-inflammatory treatments including inhaled and oral steroids, oral azithromycin and other antibiotics and inhaled antibiotics including aztreonam and tobramycin in any form. We examined ivacaftor or ivacaftor-lumacaftor combination medication effects because they alter airway physiology (3). In each case, we examined the models for independent effects and interactions with potential biomarkers that could indicate mediation of medication effects. We assessed the impact of using Global Lung Initiative equations (23) for estimating FEV₁% instead of NHANES III equations (15).

193

194 Missingness of Biomarker Measurements

195 Some sputum samples were small, preventing some biomarker measurements. We preferentially assayed NE, HMGB1 and Calprotectin (12). To evaluate missingness associated bias, we performed multiple imputation 196 by chained equations (24) for completely missing biomarker values using times to next exacerbation, non-197 198 missing biomarker values, age, sex, FEV₁%, weight-for-age z-score and number of prior pulmonary exacerbations. We performed three analyses, first, using a dataset with deletion of records with biomarkers that 199 were completely or partially unmeasured, second, using records with deletion of records with completely 200 unmeasured biomarkers but retaining records with partial measurements and third, with all records with 201 imputed values as needed, seeking evidence that missingness was other than completely at random. 202

204 Results

205 Patients and Clinical Measurements

206 We enrolled 114 from Mountain West CF Consortium (MWCFC) patients and collected sputum samples from December 8, 2014 through January 16, 2016. All patients completed follow up to the next pulmonary 207 exacerbation after enrollment or were censored at study end which occurred up to 2.65 years after enrollment. 208 209 Characteristics differed between patients who had at least one pulmonary exacerbation or had none 210 within one year post-enrollment. The differences suggested that the 5-year prognostic risk score (4, 5), FEV_1 %, 211 number of exacerbations in the year prior to enrollment and weight-for-age z-score are potential clinical confounders, mediators or both for time to next exacerbation (Table 1). No other variable incorporated in the 5-212 year prognostic risk score or methicillin resistant Staphylococcus aureus (MRSA) or Pseudomonas aeruginosa 213 214 significantly differed between patients with and without an exacerbation during one year follow up. Kaplan-Meier analysis, logistic regression and proportional hazards modeling found that FEV₁%, 215 number of prior pulmonary exacerbations, weight-for-age z-score and diabetes were associated with time to next 216 217 exacerbation within a year of enrollment (Supplemental Figure 1, Supplemental Table 3A-B). Proportional hazards modeling confirmed these associations (Supplemental Tables 3B-C) and confirmed these specific 218 clinical markers as potential confounders, mediators or both (10, 11). The remaining prognostic risk score 219 220 variables, MRSA or Pseudomonas aeruginosa infection status were not associated with time to next exacerbation. 221

222

223 Biomarkers

Biomarker measurements outside the limits of detection were adjusted after log transformation
(Supplemental Table 4), to preserve partial information and retain as many patients as possible for analysis.
Multiple correlations between biomarkers remained significant after Bonferroni correction (Supplemental Table
5) suggesting that confounding and mediation may exist among the biomarkers themselves.

229 Biomarkers, Confounding and Mediation Analyses

230	We found multiple univariable associations among biomarkers by proportional hazards modeling for
231	time to next pulmonary exacerbation. The results suggest that some potential biomarkers may be causal
232	variables for time to next pulmonary exacerbation (11) (Table 2 and Supplemental Table 6).
233	We evaluated confounding and mediation by clinical variables (Supplemental Figure 2) and found
234	associations between different subsets of our markers with each clinical variable except sex (Table 3 and
235	Supplemental Table 7A-E). With a false discovery rate (FDR) <0.001, three biomarkers were significantly
236	associated with FEV1%, secretory leukoprotease inhibitor (SLPI), NE and myeloperoxidase (MPO), and for an
237	FDR <0.01, an additional three were significant, soluble receptor for advanced glycation end-products
238	(sRAGE), matrix metallopeptidase 9 (MMP9) and extracellular newly identified receptor for advanced
239	glycation end-products (ENRAGE) (Supplemental Figure 3). S100A8 was likely to be associated with weight-
240	for-age z-score (Table 3). Altogether, these findings suggest a potential for confounding or mediation by these
241	clinical markers (11).
242	By definition, age, sex, and prior pulmonary exacerbations, cannot mediate associations between
243	biomarkers and time to next exacerbation. Thus, we treated them as confounders in further modeling with
244	biochemical markers of inflammation.
245	We evaluated weight-for-age z-score, diabetes and FEV_1 % as potential confounders, mediators or both.
246	In proportional hazards models of weight-for-age z-score and diabetes for time to next exacerbation, the hazard
247	ratios and <i>p</i> -values for the biomarkers used as adjustment variables (Table 4 and Supplemental Tables 8A-C)
248	were similar to those found in earlier models of the biomarkers alone for time to next exacerbation (Table 2 and
249	Supplemental Table 6). Weight-for-age z-score and diabetes are unlikely to be confounders or mediators of
250	

250 inflammation.

Estimated biomarker hazard ratios were weaker and uniformly non-significant when used as adjustments in proportional hazards models of FEV₁% for time to next exacerbation (Table 4 and Supplemental Tables 8A-C). FEV₁% partially mediates the association between inflammation and time to next exacerbation and should be excluded from further models (11).

255

256 Biomarkers and Pulmonary Exacerbations

257	Multivariable proportional hazards models of each potential biomarker including age, sex and prior
258	pulmonary exacerbations as confounders for time to next pulmonary exacerbation (10) found 14 inflammatory
259	markers with hazard ratios for time to next exacerbation with $p < 0.2$ (Table 5 and Supplemental Table 9).
260	Among these, setting false discovery rate (FDR) < 0.2 sets an 80% likelihood suggesting eight of the first ten
261	have true associations with time to next exacerbation (Supplemental Figure 4). Setting the FDR < 0.01 shows
262	ENRAGE and MPO each have > 99% chance of being true findings (Table 5).

263

264 Sensitivity Analyses

Adding inflammation modifying treatments as confounders to the proportional hazards models adjusted by age, sex and number of prior exacerbations did not substantially modify coefficients for any biomarker. Use of corticosteroids, inhaled, oral or both, chronic azithromycin, inhaled aztreonam, tobramycin, each alone or alternating every other month had no significant independent associations with time to next exacerbation nor interactions with the biomarker variables in each model. Coefficients (Table 5) remained stable throughout sensitivity testing suggesting that results are not due to anti-inflammatory treatments.

271 Seven patients used ivacaftor or ivacaftor-lumacaftor, but their use had no independent effect or 272 interaction, and individual biomarker variable effects were stable throughout testing. Use of Global Lung 273 Initiative equations (23) to calculate FEV_1 % instead of NHANES III led to similar results and identical 274 interpretations and conclusions.

275

276 Biomarker Measurement Missingness

We repeated models to understand the impact of partially missing information due to biomarker measurements outside detection limits and completely missing data due to insufficient samples. Analyses excluding patients with partially missing data produced similar results for models derived from using complete data sets. Analyses with missing data imputed using multiple imputation with chained equations produced

similar model results from using complete data sets (Supplemental Tables 6-9). We found no evidence of bias
for any relationship examined.

283

284 Discussion

We measured 24 sputum biomarkers from 114 randomly chosen, clinically stable adolescents and adults 285 with CF to validate prior observations for calprotectin, NE and HMGB1 (6-8) and to explore causal inference, 286 287 confounding (10) and mediation (11) between an expanded list of inflammatory biomarkers and clinical 288 outcomes. After evaluation for confounders and mediators of biomarker effects, we found potential associations with ten different molecules: ENRAGE, MPO, sRAGE, ICAM1, NE, chitinase-3-like 1 protein (YKL40), 289 290 thymus and activation regulated chemokine (TARC), MMP9, IL1B and IL5 (Table 5). At least eight are 291 associated with time to next pulmonary exacerbation (Supplemental Figure 4). FEV₁% mediates biomarker effects and was excluded from every model, while age, sex, number of prior pulmonary exacerbations were 292 confounders and were included (10, 11). Results were insensitive to anti-inflammatory treatments or ivacaftor, 293 294 although the latter was infrequently used. Severe CF lung disease continues to steadily decrease as treatments with CFTR modulators increase 295 (25). FEV₁% remains the single most common measure of disease severity, but it strongly mediates and 296

obscures biomarker effects (Table 4). FEV₁% poorly distinguishes between rapid or slow worsening of lung
disease (4). As CF disease severity lessens (26), FEV₁% will become less useful, and biomarkers measuring
inflammation with appropriate adjustments for confounding will be increasingly useful for understanding
clinical status (Figure 1) and providing attractive intervention targets.

Biomarkers associated with time to next exacerbation fall into several categories (Figure 2). ENRAGE and sRAGE are constituents of RAGE-axis related inflammation. ENRAGE is a high avidity RAGE ligand that indicates neutrophil activity (27). It is elevated in CF airways in infancy (28) and is associated with low FEV₁ and CF-related diabetes (29). ENRAGE increases during pulmonary exacerbation and falls with antibiotic treatment (30). Beyond CF, higher ENRAGE is associated with cigarette smoking-induced injury (31), higher coronary artery disease risk (32) and higher chronic kidney disease mortality (33). ENRAGE increases in

307	bronchoalveolar lavage in the acute respiratory distress syndrome (ARDS) and decreases with recovery (34). In
308	SARS-CoV-2-associated ARDS, it rises with increasing severity and falls with recovery (35).
309	ENRAGE most strongly correlated with MMP9 and MPO (Supplemental Table 5) suggesting
310	associations between RAGE axis inflammation and both protease and oxidative stress mediated injuries.
311	SRAGE is the soluble form of the membrane bound RAGE receptor. Strong correlations with NE (0.80), MMP9
312	(0.65) and IL1 β (0.69) may indicate associations between RAGE axis inflammation and neutrophil-derived
313	protease mediated injuries. MPO, ICAM1, NE, YKL40, TARC and MMP9 reflect the important roles of
314	neutrophils, neutrophil-associated proteases (MMP9) (7, 36) and reactive oxygen species (MPO) (37) in CF
315	airway inflammation (Figure 2).
316	SLPI, NE and MPO (Supplemental Figure 3) were associated with FEV ₁ % with a FDR set at 0.001. For
317	FDR set at 0.01, we found another three biomarkers, sRAGE, MMP9 and ENRAGE. Anti-protease SLPI
318	opposes NE, MMP9 and proteinase 3 (PR3) activities (7, 37, 38) and was associated with higher FEV ₁ % (Table
319	3). These findings suggest that RAGE-axis, protease-anti-protease imbalance and reactive oxygen species
320	sources of inflammation might cause lower FEV_1 % (Supplemental Figure 5).
321	Contrary to pre-study expectations (6-8), Calprotectin, NE and HMGB1 were not associated with time
322	to next pulmonary exacerbation. However, the study redemonstrated associations between these molecules and
323	prior pulmonary exacerbations (Table 3 and Supplemental Table 7D), and they are markers of neutrophil
324	activity and part of the RAGE-axis of inflammation. These partial validation results reinforce that this study
325	differs from prior studies in at least two substantial ways. First, we recruited randomly selected clinically stable
326	(39) rather than mixed stable and unstable serial patients. Second, our analyses evaluated confounding and
327	mediation by clinical covariables (10, 11).
328	Our study has limitations. Because we are pursuing explanatory airway inflammation models (13), no
329	methods of model selection are sufficient (10) to confidently produce a multivariable panel of inflammatory
330	biomarkers. However, our current observational work will be useful prior to launching new observational and

331 other types of investigations to discover a multivariable biomarker model. Although many study patients took

332 every prior effective treatment, due to study timing, only 6% received CFTR modulators. Our study does not

333 confirm whether CFTR modulators reduce airway inflammation. Further studies are needed, however, modulators are associated with reduced sputum production, so alternative sampling methods may be required. 334 Finally, our explanatory models infer but cannot confirm causal relationships. RAGE axis inflammation, 335 protease mediated injury and oxidative stress are strongly associated with future exacerbation. FEV₁%, the 336 single most important predictor of survival in CF, mediates the association of inflammatory markers with time 337 to next pulmonary exacerbation. Further studies in cell culture or animal models or human trials of anti-338 339 proteases, anti-oxidants, RAGE inhibiting agents or a combination are needed to provide the information to 340 improve causal inference and potentially treat the CF airway inflammation. Because of the importance and commonality of these inflammatory processes in other lung diseases such as ARDS, progress in CF with novel 341 342 anti-inflammatory treatments may have broad application.

343

344 Author Contributions

TGL is the manuscript guarantor and takes responsibility for the integrity of the work from inception to 345 346 publication. TGL drafted the initial manuscript; all authors contributed interpretive insights, edits and corrections. MH created the graphical abstract with assistance from TGL and assisted TGL in turn to diagram 347 interactions between biomarkers and lung disease. DRC initiated and oversaw development of the statistical 348 349 plan for randomized enrollment by TGL, FRA, RK with additional inputs from JLJ, KRP and SDS, TGL, FRA, DRC, CK, RK and RDS performed the statistical analysis. JLJ oversaw IRB submissions throughout the 350 MWCFC with help at each site from NA, DD, JAF, BG, CMK, OM, KAP, KRP, AJR, JBV and RY, TGL, NA, 351 352 PSB. BAC. CLD. DD. JAF. BG. JLJ. TH. JRH. CMK. YL. JL. NL. OM. CN. KAP. KRP. ALO. PR. AJR. SDS. JLT-C, JBV, RY, JPC, JSE, KNO developed and performed patient enrollment processes, sample collections and 353 clinical annotations. JLJ oversaw the work preceding the study planning meeting with critical assistance from 354 KAP, JAF and JBV. JLJ oversaw and coordinated logistics and regulatory documentation for the entire study. 355 TGL, JAF, JLJ, YL, KAP and JBV developed the sputum processing protocol, JAF, JLJ, KAP, YL and JBV 356 357 provided central and on-site laboratory training. TGL and JLJ performed site initiation visits. JLJ and KAP centrally monitored data collection. JAF. KAP and JBV performed interim and end-of-study site visits to verify 358

359	data integrity and regulatory compliance. KAP developed and implemented REDCap electronic data capture
360	(40) with input from TGL, JAF, JLJ and JBV. KAP oversaw data entry, query generation and resolution and
361	generation of raw data reports. JBV with assistance from JAF, JLJ and YL developed protocols and oversaw
362	specimen shipping by NA, DD, BG, CMK, OM, KRP, AJR and RY. JAF, JLJ, JBV, KAP and YL received,
363	handled and successfully managed sputum specimens centrally despite shipment damage, floods, power
364	outages, freezer and complete building services failures. YL performed ELISA studies in Utah. SS oversaw NE
365	activity determinations in Colorado. TGL obtained funding with assistance from FRA, JLJ and SDS and
366	additional help from PSB, BAC, CLD, RK, JL, CN and DRC. JPC, JSE and KNO were the Study Advisory
367	Committee and contributed to multiple study aspects. All authors had access to complete raw and processed
368	datasets from this study.
369	The results, interpretations and opinions expressed in this work are those of the authors and do not
370	necessarily represent the views of their institutions, the NIH, NHLBI, NCATS, NSF, the Veteran's
371	Administration, the Margolis Foundation, the Claudia Ruth Goodrich Stevens Family, the US CF Foundation,
372	the European CF Society or the Medical Research Council in the UK or any of the sponsors of clinical trials that
373	provided other support for individual authors or the governments of the US or the UK.
374	
375	Acknowledgments
376	We thank the study participants and their families. We thank Mike Mitchell in the Pulmonary Laboratory at the
377	University of Utah for technical assistance.
378	
379	Funding
380	This project was supported by the CF Foundation (CFF) (LIOU13A0, LIOU14Y4), the National Center for
381	Advancing Translational Science at the National Institutes of Health (NCATS/NIH 8UL1TR000105 [formerly
382	UL1RR025764]), the Ben B and Iris M Margolis Foundation of Utah and the Claudia Ruth Goodrich Stevens
383	Endowment Fund. Neither the project sponsors nor any sources of other support had direct roles in development

and conduct of the study. None of the sponsors of clinical trials mentioned in the competing interests and other

385 support section that follows participated in any way with this trial.

386

387 Potential Conflicts of Interest and Other Support

- 388 TGL, JAF, JLJ, YL, KAP and JBV received other support from the CFF (CC132-16AD, LIOU14Y0,
- 389 LIOU14P0) and the National Heart Lung and Blood Institute (NHLBI) of the National Institutes of Health
- 390 (NIH) (R01 HL125520) and received support during the current study for performing clinical trials from
- 391 Abbvie, Calithera Biosciences, Corbus Pharmaceuticals, Gilead Sciences, Laurent Pharmaceuticals, Nivalis
- 392 Therapeutics, Novartis, Proteostasis, Savara Pharmaceuticals, Translate Bio and Vertex Pharmaceuticals. FRA
- 393 received additional other support from the NHLBI/NIH (R01 HL125520), the National Science Foundation
- 394 (EMSW21-RTG) and the Margolis Foundation of Utah. PSB received other support from the CFF (Center and
- 395 TDC grants) and the NHLBI/NIH (U01 HL114623) and received support for a clinical trial from Alcresta
- 396 Therapeutics. BAC received other support from the CFF (C112-12, C112-TDC09Y, 10063SUB,
- 397 41339154.s132P010379SUB) and received support for clinical trials from Genentech, Novartis and Vertex
- 398 Pharmaceuticals. CLD received other support from the CFF (C004-11, C004-TDC09Y, DAINES11Y3) and
- 399 from the Health Resources and Services Administration (T72MC00012). JAF is now an employee of ICON plc,
- 400 a clinical research organization involved in various trials pertinent to CF; She and ICON had no direct
- 401 involvement in performance of the study following the change in affiliation. TH received other support from the
- 402 CFF (PACE, Center Grant) and received support for clinical trials from Celtaxsys and Vertex Pharmaceuticals.
- 403 JRH received other support from the NHLBI/NIH (HHSN268200900018C) and the Veterans Administration
- 404 Healthcare System (I01 BX001533). JL received other support from the CFF (C017-11AF). CN received other
- 405 support from the CFF (C138-12). PR received other support from the CFF (C003-12, C003-TDC09Y). SDS
- 406 received other support from the CFF (AQUADEK12K1, SAGEL11CS0, GOAL13K2, NICK13A0,
- 407 SAGEL14K1, NICK15R0) and the NHLBI/NIH (U54 HL096458) and the NCATS/NIH (Colorado CTSA Grant
- 408 Number UL1 TR002535). JLT-C received other support from the CFF (TDC) and the NHLBI/NIH (HL103801)
- and received support for clinical trials from Vertex Pharmaceuticals. KNO is funded by the intramural research
- 410 program of the NHLBI, NIH.

411

412 **References**

 Zemanick ET et al. Airway microbiota across age and disease spectrum in cystic fibrosis. *Eur. Respir. J.* 2017;50(5). doi:10.1183/13993003.00832-2017

Granchelli AM et al. Microbial Interactions in the Cystic Fibrosis Airway. J. Clin. Microbiol.
 2018;56(8):e00354-18.

3. Elborn JS. Cystic fibrosis. Lancet 2016;388(10059):2519-2531.

4. Liou TG et al. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001;153(4):345-52.

5. Liou TG, Kartsonaki C, Keogh RH, Adler FR. Evaluation of a five-year predicted survival model for cystic fibrosis in later time periods. *Sci Rep* 2020;10(1):6602.

6. Liou TG et al. Sputum biomarkers and the prediction of clinical outcomes in patients with cystic fibrosis. *PLoS ONE* 2012;7(8):e42748.

7. Sagel SD, Wagner BD, Anthony MM, Emmett P, Zemanick ET. Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis. *Am. J. Respir. Crit. Care Med.* 2012;186(9):857–865.

8. Gray RD et al. Sputum and serum calprotectin are useful biomarkers during CF exacerbation. *J. Cyst. Fibros.* 2010;9(3):193–198.

9. Reid PA et al. Measurement of Serum Calprotectin in Stable Patients Predicts Exacerbation and Lung Function Decline in Cystic Fibrosis. *Am J Respir Crit Care Med* 2015;191(2):233–236.

10. Lederer DJ et al. Control of Confounding and Reporting of Results in Causal Inference Studies. Guidance for Authors from Editors of Respiratory, Sleep, and Critical Care Journals. *Annals ATS* 2019;16(1):22–28.

11. Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. *J Pers Soc Psychol* 1986;51(6):1173–1182.

12. Liou TG et al. Prospective Multicenter Randomized Patient Recruitment and Sample Collection to Enable Future Measurements of Sputum Biomarkers of Inflammation in an Observational Study of Cystic Fibrosis. *BMC Medical Research Methodology* 2019;19(1):88.

13. Shmueli G. To Explain or to Predict?. Statistical Science 2010;25(3):289-310.

14. Standardization of Spirometry, 1994 Update. American Thoracic Society. Am. J. Respir. Crit. Care Med.

1995;152(3):1107–1136.

15. Hankinson JL, John R. Odencrantz, Kathleen B. Fedan. Spirometric reference values from a sample of the general U.S. population. *Am. J. Respir. Crit. Care Med.* 1999;159(1):179–187.

Tukey JW. *Exploratory data analysis*. Reading, Massachusettes: Addison-Wesley Publishing Company;
 1977:

17. Kaplan EL, Meier P. Nonparametric Estimation from Incomplete Observations. *Journal of the American Statistical Association* 1958;53(282):457–481.

18. Cox DR. The Regression Analysis of Binary Sequences. *Journal of the Royal Statistical Society. Series B (Methodological)* 1958;20(2):215–242.

19. Cox DR. Regression models and life-tables. J R Stat Soc B Met 1972;34(2):187-220.

20. Venables WN, Ripley BD. Modern Applied Statistics with S. Springer New York; 2010:

21. Dasenbrook EC et al. Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. *JAMA* 2010;303(23):2386–2392.

22. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society. Series B (Methodological)* 1995;57(1):289–300.

23. Quanjer PH et al. Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations. *Eur Respir J* 2012;40(6):1324–1343.

24. Buuren S van, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure covariates in survival analysis. *Statistics in Medicine* 1999;18(6):681–694.

25. Rubin JL et al. Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor/ivacaftor. *Ther Adv Respir Dis* 2019;13:1753466618820186.

26. Bayfield KJ et al. Time to get serious about the detection and monitoring of early lung disease in cystic fibrosis. *Thorax* 2021;thoraxjnl-2020-216085.

27. Makam M et al. Activation of critical, host-induced, metabolic and stress pathways marks neutrophil entry into cystic fibrosis lungs. *Proc. Natl. Acad. Sci. U.S.A.* 2009;106(14):5779–5783.

28. McMorran BJ et al. Novel neutrophil-derived proteins in bronchoalveolar lavage fluid indicate an exaggerated inflammatory response in pediatric cystic fibrosis patients. *Clin. Chem.* 2007;53(10):1782–1791.

Hunt WR, Helfman BR, McCarty NA, Hansen JM. Advanced glycation end products are elevated in cystic fibrosis-related diabetes and correlate with worse lung function. *J. Cyst. Fibros.* 2016;15(5):681–688.
 Foell D et al. Expression of S100A12 (EN-RAGE) in cystic fibrosis. *Thorax* 2003;58(7):613–617.
 Reynolds PR et al. RAGE: developmental expression and positive feedback regulation by Egr-1 during cigarette smoke exposure in pulmonary epithelial cells. *Am. J. Physiol. Lung Cell Mol. Physiol* 2008;294(6):L1094-1101.

32. Ligthart S et al. EN-RAGE: a novel inflammatory marker for incident coronary heart disease. *Arterioscler*. *Thromb. Vasc. Biol.* 2014;34(12):2695–2699.

33. Isoyama N et al. Plasma S100A12 and soluble receptor of advanced glycation end product levels and mortality in chronic kidney disease Stage 5 patients. *Nephrol. Dial. Transplant.* 2015;30(1):84–91.

34. Wittkowski H et al. Neutrophil-derived S100A12 in acute lung injury and respiratory distress syndrome. *Crit Care Med* 2007;35(5):1369–1375.

35. Arunachalam PS et al. Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans. *Science* 2020;369(6508):1210–1220.

36. Sagel SD, Kapsner RK, Osberg I. Induced sputum matrix metalloproteinase-9 correlates with lung function and airway inflammation in children with cystic fibrosis. *Pediatr Pulmonol* 2005;39(3):224–32.

37. Chandler JD et al. Myeloperoxidase oxidation of methionine associates with early cystic fibrosis lung disease. *Eur. Respir. J.* 2018;52(4). doi:10.1183/13993003.01118-2018

38. Rao NV, Marshall BC, Gray BH, Hoidal JR. Interaction of secretory leukocyte protease inhibitor with proteinase-3. *Am J Respir Cell Mol Biol* 1993;8(6):612–6.

39. Cox DR. Planning of Experiments. New York: Wiley; 1958:

40. Harris PA et al. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform* 2009;42(2):377–381.

Characteristic or	All Patients	Exacerbations Obs		
Chronic Treatment Received	n = 114	None n = 42	One or More n = 72	<i>p</i> value
Years of Age [*]	26.3 (12.8 to 68.2)	27.8 (12.8 to 68.2)	24.5 (13 to 67.1)	0.084 [§]
FEV ₁ % [*]	72.1 (19.6 to 119)	80.5 (30.2 to 119)	66.5 (19.6 to 113)	0.018 [§]
Exacerbations in Year Prior to Enrollment [*]	1 (0 to 7)	0 (0 to 5)	2 (0 to 7)	<0.001¶
Weight-for Age z- score*	-0.118 (-3.29 to 2.72)	-0.0257 (-1.41 to 2.12)	-0.147 (-3.29 to 2.72)	0.23 [§]
Female [†]	0.46	0.43	0.49	0.69 [‡]
Diabetes [†]	0.22	0.095	0.29	0.027 [‡]
Pancreatic Sufficiency [†]	0.079	0.12	0.056	0.29‡
MSSA Infection [†]	0.45	0.48	0.43	0.78^{\ddagger}
<i>Burkholderia cepacia</i> Complex Infection [†]	0.026	0	0.042	0.30
5-Year Prognostic Risk Score [*]	3.16 (-1.8 to 6.08)	3.73 (0.676 to 6.08)	2.76 (-1.8 to 5.59)	<0.001§
Inhaled Steroids	0.59	0.5	0.64	0.21‡
Oral Steroids	0.07	0.12	0.042	0.14‡
Any Steroids	0.61	0.55	0.64	0.45 [‡]
Azithromycin	0.54	0.48	0.58	0.36‡
Other Oral Antibiotic	0.11	0.095	0.12	0.77
Any Oral antibiotics	0.61	0.5	0.67	0.12 [‡]
Inhaled Tobramycin	0.33	0.31	0.35	0.84^{\ddagger}
Inhaled Aztreonam	0.35	0.29	0.39	0.36 [‡]
Any Inhaled Antibiotics	0.61	0.52	0.67	0.19‡
Any Antibiotics	0.82	0.74	0.86	0.17 [‡]
Ivacaftor	0.044	0.071	0.028	0.36
Ivacaftor-Lumacaftor	0.018	0	0.028	0.53
Ivacaftor or Ivacaftor- lumacaftor	0.061	0.071	0.056	0.71

413 Table 1. Enrollment Characteristics and Treatments for	Patients by Exacerbations Observed Within One Year
--	--

414 * Median (Range)

415 [†] Decimal Fraction for Status

416 [§]Linear Regression

417 [¶]Quasipoisson Regression

418 $\frac{1}{\chi}$ -square Test

419 Fisher's Exact Test

420

421

423 <u>Table 2. Univariable Biomarker Proportional Hazards Models of Time to Next Exacerbation</u>*

Biomarker	Estimate	SE	Hazard Ratio	р	95% CI of the Hazard Ratio
MPO	0.24	0.10	1.28	0.01	1.06 to 1.54
NE	0.18	0.08	1.20	0.02	1.03 to 1.39
S100A9	-0.27	0.12	0.76	0.03	0.6 to 0.971
s RAGE	0.20	0.09	1.22	0.03	1.02 to 1.45
ENRAGE	0.20	0.09	1.22	0.03	1.02 to 1.46
IL1β	0.16	0.08	1.17	0.04	1.01 to 1.37
YKL40	0.19	0.10	1.21	0.06	0.996 to 1.46
IL17A	0.30	0.17	1.35	0.08	0.967 to 1.88
PR3	0.14	0.09	1.15	0.11	0.967 to 1.37
ICAM1	0.24	0.15	1.27	0.12	0.938 to 1.71
IL8	0.36	0.24	1.44	0.13	0.902 to 2.29
Calprotectin	0.05	0.04	1.06	0.13	0.984 to 1.13
MMP9	0.13	0.08	1.13	0.13	0.962 to 1.34

424 *See Supplemental Table 6 for results for all biomarkers.

425 Table 3. Unadjusted Associatio	ns between Biomarkers and	Clinical Characteristics.*
------------------------------------	---------------------------	----------------------------

Clinical	Clinical Univariable Models				s
Variable	Biomarkers	Estimates	SE	р	95% CI
	SLPI^	-2.01	0.73	0.007	-3.45 to -0.57
Age (years) [†]	NE	1.80	0.75	0.016	0.37 to 3.33
	sRAGE	2.00	0.84	0.02	0.33 to 3.61
	S100A8*	0.43	0.11	< 0.001	0.21 to 0.64
	IL10°	0.33	0.12	0.01	0.09 to 0.56
Weight for Age	IL6°	0.30	0.11	0.01	0.08 to 0.53
z-score [†]	GMCSF°	0.65	0.24	0.01	0.17 to 1.13
	IFNγ^	0.43	0.20	0.03	0.05 to 0.82
	ICAM1^	0.26	0.13	0.04	0.01 to 0.50
	IL10°	-0.15	0.05	0.002	-0.25 to -0.05
Diabetes Status [†]	IL17A	-0.13	0.06	0.02	-0.24 to -0.02
	IFNγ	-0.19	0.08	0.02	-0.35 to -0.03
	TARC	-0.31	0.14	0.03	-0.58 to -0.04
	Calprotectin	0.13	0.049	0.012	0.0299 to 0.223
Prior Pulmonary		0.47	0.22	0.033	0.0442 to 0.897
Exacerbations [§]	IL10	-0.41	0.20	0.037	-0.797 to -0.0286
	NE	0.20	0.099	0.05	0.00231 to 0.392
	SLPI [¶]	6.39	1.24	< 0.001	3.97 to 8.81
	NE¶	-5.63	1.30	< 0.001	-8.17 to -3.09
	MPO [¶]	-6.33	1.56	< 0.001	-9.38 to -3.27
	sRAGE [*]	-5.24	1.47	< 0.001	-8.12 to -2.36
	MMP9 [*]	-5.03	1.50	0.001	-7.97 to -2.09
	ENRAGE [*]	-5.32	1.64	0.001	-8.53 to -2.12
	IL1 $\beta^{ }$	-3.74	1.36	0.007	-6.41 to -1.07
$\text{FEV}_1\%^\dagger$	S100A8	6.41	2.54	0.01	1.42 to 11.4
	PR3	-4.11	1.65	0.01	-7.35 to -0.87
	Calprotectin°		0.69	0.02	-2.91 to -0.22
	IL8^	-8.00	4.03	0.05	-15.9 to -0.10
	IL10^	5.28	2.69	0.05	0.017 to 10.5
	YKL40^	-3.56	1.85	0.06	-7.19 to 0.08

426 * See Supplemental Table 7A-E for results with all potential biomarkers. [†]Linear Regression; [§]Quasipoisson regression. [¶]Significant 427 with FDR < 0.001; [†]Significant with FDR < 0.01; [|]Significant with FDR < 0.01; [|]Significant 427 with FDR < 0.01; [†]Significant 428 with FDR < 0.01; [†]Significant 428 with 728 with 72

433	Table 4. Biomarkers as Univariable Adjustments to Clinical Variables in Proportional Hazards Models of Time to Next
434	Exacerbation.

Clinical	Adjustment Univariables							
Clinical Variable [*]	Biomarkers		SE	Hazard Ratio	р	95% CI of the Hazard Ratio		
Weight for Age <i>z</i> -score	MPO^	0.29	0.09	1.33	0.002	1.11 to 1.6		
	NE	0.17	0.07	1.18	0.03	1.02 to 1.37		
	S100A9	-0.27	0.12	0.76	0.03	0.597 to 0.971		
	sRAGE	0.19	0.09	1.21	0.04	1.01 to 1.44		
	ENRAGE^	0.25	0.09	1.29	0.01	1.07 to 1.55		
	IL1β	0.17	0.08	1.18	0.03	1.02 to 1.37		
	YKL40	0.19	0.09	1.20	0.05	1 to 1.45		
	IL17A	0.43	0.18	1.54	0.02	1.08 to 2.2		
	PR3	0.12	0.09	1.13	0.16	0.952 to 1.33		
	ICAM1	0.32	0.16	1.38	0.04	1.02 to 1.87		
	IL8	0.42	0.24	1.52	0.08	0.956 to 2.41		
	Calprotectin	0.06	0.04	1.06	0.10	0.989 to 1.14		
	MMP9	0.16	0.09	1.17	0.07	0.989 to 1.39		
Diabetes Status	MPO	0.22	0.10	1.24	0.03	1.03 to 1.5		
	NE	0.17	0.08	1.19	0.03	1.02 to 1.38		
	S100A9	-0.25	0.13	0.78	0.05	0.607 to 0.995		
	sRAGE	0.19	0.09	1.21	0.03	1.02 to 1.45		
	ENRAGE	0.18	0.09	1.19	0.06	0.993 to 1.43		
	IL1β	0.15	0.08	1.17	0.05	0.999 to 1.36		
	YKL40	0.17	0.10	1.19	0.09	0.975 to 1.44		
	IL17A	0.30	0.16	1.34	0.07	0.973 to 1.86		
	PR3	0.12	0.09	1.13	0.17	0.946 to 1.35		
	ICAM1	0.24	0.16	1.27	0.12	0.939 to 1.72		
	IL8	0.28	0.23	1.32	0.23	0.839 to 2.09		
	Calprotectin	0.06	0.04	1.06	0.11	0.986 to 1.14		
	MMP9	0.11	0.08	1.12	0.19	0.946 to 1.32		
FEV ₁ %	MPO	0.19	0.10	1.21	0.06	0.99 to 1.48		
	NE	0.14	0.08	1.15	0.09	0.98 to 1.35		
	S100A9	-0.24	0.12	0.79	0.05	0.619 to 1		
	s RAGE	0.14	0.10	1.15	0.14	0.954 to 1.39		
	ENRAGE	0.15	0.10	1.16	0.12	0.961 to 1.41		
	IL1β	0.13	0.08	1.14	0.11	0.973 to 1.33		
	YKL40	0.15	0.10	1.16	0.14	0.951 to 1.41		
	IL17A	0.24	0.17	1.28	0.16	0.908 to 1.79		
	PR3	0.11	0.09	1.12	0.22	0.935 to 1.35		
	ICAM1	0.11	0.05	1.12	0.22	0.888 to 1.63		
	IL8			1.20				
		0.29	0.24		0.23	0.83 to 2.14		
	Calprotectin	0.04	0.04	1.04	0.34	0.963 to 1.11		
	MMP9 nental Table 8	0.08	0.09	1.08	0.37	0.909 to 1.29 Significant wi		

* See Supplemental Table 8A-C for results of all biomarkers. * Significant with FDR = 0.001; * Significant with FDR = 0.01; * Significant with FDR = 0.05; * FDR < 0.1; * FDR < 0.2.

Table 5. Biomarkers in Adjusted^{*} Proportional Hazards Models of Time to Next Exacerbation.

Diamanhana	Estimates	SE	Hazard	р	95% CI of the
Biomarkers	Estimates		Ratio		Hazard Ratio
ENRAGE°	0.30	0.10	1.35	0.004	1.1 to 1.65
MPO°	0.26	0.099	1.30	0.008	1.07 to 1.57
sRAGE^	0.20	0.088	1.23	0.021	1.03 to 1.46
ICAM1^	0.38	0.16	1.46	0.021	1.06 to 2.02
NE^	0.18	0.077	1.19	0.022	1.03 to 1.39
YKL40^	0.23	0.10	1.26	0.024	1.03 to 1.53
TARC^	1.00	0.46	2.72	0.031	1.10 to 6.74
MMP9^	0.18	0.09	1.20	0.039	1.01 to 1.43
IL1B^	0.16	0.08	1.17	0.049	1.00 to 1.37
IL5^	0.58	0.31	1.79	0.062	0.97 to 3.29
IL17A	0.28	0.17	1.32	0.098	0.95 to 1.83
S100A9	-0.20	0.12	0.823	0.12	0.645 to 1.05
IFNγ	0.37	0.26	1.44	0.16	0.861 to 2.41
PR3	0.12	0.094	1.13	0.19	0.94 to 1.36

^{*}Adjusted by Age, Sex and Number of Prior Pulmonary Exacerbations. See Supplemental Table 9 for results for all biomarkers. ^{*}Significant with FDR = 0.001; ^{*}FDR = 0.01; [|]FDR = 0.05; [°]FDR < 0.1; [^]FDR < 0.2.





Figure 1. Kaplan Meier Plots Based on Proportional Hazard Ratio Estimates for Individual Patients. We
 categorized patients by hazard ratios higher or lower than the median estimated using a full model including log
 transformed values of ENRAGE adjusted by age, sex and number of prior pulmonary exacerbations as
 confounders. We drew Kaplan-Meier plots and compared with plots based on hazard ratios estimated using
 model A. excluding ENRAGE data, B. excluding prior pulmonary exacerbations, C. including only
 ENRAGE data, and D. including only prior pulmonary exacerbations. The numbers at risk for A and D
 differ from other plots because median hazard ratios including exacerbation count data did not divide patients

451 into equal groups.



- 452 Figure 2. Schematic Model of Inflammation in the CF Airway. Using sputum and clinical data, we
- 453 measured potential inflammatory biomarkers to investigate pulmonary exacerbations of CF. We found that
- 454 RAGE Axis related inflammation and neutrophil related protease-anti-protease imbalance and oxidative stress
- 455 are the most likely pathophysiologic processes involved.